Cargando…

Cardio-renal protection of riociguat (BAY 63-2521) in low- and high-renin models of hypertension

Detalles Bibliográficos
Autores principales:	Kalk, Philipp, Sharkovska, Yuliya, Lawrenz, Bettina, Godes, Michael, Hoffmann, Linda Sarah, Wellkisch, Kathrin, Geschka, Sandra, Relle, Katharina, Hocher, Berthold, Stasch, Johannes-Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3313342/ http://dx.doi.org/10.1186/1471-2210-9-S1-P30

Ejemplares similares

Riociguat prevents fibrotic tissue remodelling and improves survival in salt-sensitive Dahl rats
por: Geschka, Sandra, et al.
Publicado: (2011)

No pharmacodynamic (PD) and pharmacokinetic (PK) interaction of riociguat (BAY 63-2521) and aspirin
por: Frey, Reiner, et al.
Publicado: (2011)

Warfarin pharmacodynamics and pharmacokinetics are not affected by the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
por: Frey, Reiner, et al.
Publicado: (2009)

Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension
por: Mittendorf, Joachim, et al.
Publicado: (2009)

Soluble Guanylate Cyclase Stimulation Prevents Fibrotic Tissue Remodeling and Improves Survival in Salt-Sensitive Dahl Rats
por: Geschka, Sandra, et al.
Publicado: (2011)

Chronic activation of heme free soluble guanylate cyclase leads to cardio-renal protection in experimental hypertension
por: Hoffmann, Linda S, et al.
Publicado: (2013)

Additional stimulation of sGC on top of standard treatment with ARB`s may offer a new therapeutic approach for the treatment of diabetic nephropathy resistant to ARB treatment alone
por: Alter, Markus, et al.
Publicado: (2011)

Platelet inhibitory effects of the NO independent sGC stimulator riociguat (Bay 63-2561)
por: Reiss, Cora, et al.
Publicado: (2013)

Effects of Stimulation of Soluble Guanylate Cyclase on Diabetic Nephropathy in Diabetic eNOS Knockout Mice on Top of Angiotensin II Receptor Blockade
por: Ott, Ina M., et al.
Publicado: (2012)

Chronic Activation of Heme Free Guanylate Cyclase Leads to Renal Protection in Dahl Salt-Sensitive Rats
por: Hoffmann, Linda S., et al.
Publicado: (2015)

Impact of maternal body mass index on neonatal outcome
por: Kalk, P, et al.
Publicado: (2009)

Effects of riociguat in severe experimental pulmonary hypertension
por: Kojonazarov, Baktybek, et al.
Publicado: (2011)

Renal phenotype of Et-1 transgenic mice is modulated by androgens
por: Kalk, P, et al.
Publicado: (2009)

PB2521: STUDY OF HEMOGLOBIN S-OMAN TRAIT: NEW INSIGHTS
por: Al-Mahrouqi, Nouh, et al.
Publicado: (2023)

2521. The Potential Rise in the Incidence of Rotavirus G3P[8] in Kuwait
por: Al-Nakib, Widad Widad, et al.
Publicado: (2018)

The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats
por: Lang, Michaela, et al.
Publicado: (2011)

Riociguat: PATENT-1 Study
por: Said, Karim
Publicado: (2014)

Riociguat and cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats
por: Reinke, Yvonne, et al.
Publicado: (2015)

The Soluble Guanylate Cyclase Stimulator Riociguat Ameliorates Pulmonary Hypertension Induced by Hypoxia and SU5416 in Rats
por: Lang, Michaela, et al.
Publicado: (2012)

Riociguat Reduces Infarct Size and Post-Infarct Heart Failure in Mouse Hearts: Insights from MRI/PET Imaging
por: Methner, Carmen, et al.
Publicado: (2013)

Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat
por: Frey, Reiner, et al.
Publicado: (2017)

Inverse correlation of intact PTH, oxidized PTH as well as non-oxidized PTH with 25-hydroxyvitamin D3 in kidney transplant recipients
por: Zuo, Jiao, et al.
Publicado: (2023)

2521: Research participant 101: What you need to know before joining a research study
por: Straughn, Victoria, et al.
Publicado: (2018)

Abstract 2521: AI-enabled multiscale modeling of SARS-CoV-2 replication transcription complex
por: Arvind, Ramanathan, et al.
Publicado: (2023)

Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding
por: Rai, Nabham, et al.
Publicado: (2018)

Relaxant effect of BAY 41-2272 and BAY 58-2667 in the gastrointestinal tract of apo-sGC mice
por: Cosyns, Sarah, et al.
Publicado: (2011)

Comparison of infection risks and clinical outcomes in patients with and without SARS‐CoV‐2 lung infection under renin–angiotensin–aldosterone system blockade: Systematic review and meta‐analysis
por: Chu, Chang, et al.
Publicado: (2020)

2521 Use of forced air warming devices to induce fever-range hyperthermia in critically ill septic patients
por: Drewry, Anne M., et al.
Publicado: (2018)

Pharmacokinetic interaction of ketoconazole, clarithromycin, and midazolam with riociguat
por: Becker, Corina, et al.
Publicado: (2013)

Riociguat: Something new in pulmonary hypertension therapeutics?
por: Shanmugam, Elangovan, et al.
Publicado: (2015)

Riociguat: Clinical research and evolving role in therapy
por: Klinger, James R., et al.
Publicado: (2020)

Riociguat in Patients with CTEPH and Advanced Age and/or Comorbidities
por: Barnikel, Michaela, et al.
Publicado: (2022)

Effects of Aliskiren on Stroke in Rats Expressing Human Renin and Angiotensinogen Genes
por: Schmerbach, Kristin, et al.
Publicado: (2010)

Response to: Comment on “Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding”
por: Rai, Nabham, et al.
Publicado: (2018)

2521. VE707, a Defined Live Biotherapeutic Product for Prevention of Infection by Multidrug-Resistant Gram-Negative Bacteria
por: Medlock, Gregory, et al.
Publicado: (2023)

The clinical development of sGC modulators, riociguat and vericiguat
por: Misselwitz, Frank
Publicado: (2015)

Practical management of riociguat in patients with pulmonary arterial hypertension
por: Halank, Michael, et al.
Publicado: (2019)

An Unlikely Trio: Profound Anemia, Elevated Lactate, and Riociguat
por: Farmer, Mary Jo S, et al.
Publicado: (2022)

Overview of Riociguat and Its Role in the Treatment of Pulmonary Hypertension
por: Kenny, Marianne, et al.
Publicado: (2020)

Urinary cGMP concentrations after exposure to radio-contrast media in patient at risk for contrast media induced nephropathy (CIN) predicts 90-day morbidity and mortality
por: Hocher, Berthold, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_nqqp9lli7tn72lg9s24ahqkh3f